Patent ductus arteriosus (PDA) in very preterm newborns is associated with severe neonatal mor-bidity: intraventricular hemorrhage (IVH), bronchopulmonary dysplasia (BPD), necrotizing en-terocolitis (NEC), retinopathy of prematurity (ROP). Existing methods of management PDA do not reduce the incidence of these diseases. The efficacy of cyclooxygenase inhibitors (COX) which are currently the standard of treatment in extreme preterm infants is about 70-80%. COX inhibitors have significant side effects. On the other hand, surgical ligation of the ductus arteriosus is associated with deterioration due to cardio-pulmonary problems and long-term complications. Paracetamol has been proposed for treatment of hemodynamically significant PDA because it has a different mecha-nism of action compared with COX inhibitors and a better safety profile. Recently, expectant approach has becoming more popular, although there is not enough evidence to support it. The objective of this study is to investigate whether in preterm infants, born at a GA less than 32 weeks, with a PDA (diameter \> 1.5 mm) at a postnatal age of \< 72 h, an expectant management is non-inferior to early treatment with regard to the composite of mortality and/or severe morbidity.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
208
In the medical treatment arm the in-tention is to close the ductus arteriosus.
In the medical treatment arm the in-tention is to close the ductus arteriosus.
Expectative PDA management is character-ized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
Lviv National Medical University
Lviv, Ukraine
Incidence of bronchopulmonary dysplasia (BPD) or mortality at 36 weeks postmenstrual age (PMA)
Time frame: 36 weeks PMA
PDA re-opening rate
PDA re-opening after echocardiographically documented closure
Time frame: Day 1 up to 3 month
Closure rate of PDA within a week after the first and second course of pharmacological treatment
Time frame: Participants will be evaluated at the end of first and second course, at an expected avarage of 10 days of life
The need for surgical ductus closure
Time frame: Day 1 up to 3 month
Duration of any ventilation assist
The ventilation assist time period
Time frame: Day 1 up to 3 month
Duration of oxygen supplementation
Days on supplement oxygen
Time frame: Day 1 up to 3 month
Age of administration of full volume of enteral nutrition
Time frame: Day 1 up to 3 month
Incidence of oliguria
Time frame: In the first 14 days of life
Incidence of hypotension
Time frame: Day 1 up to 3 month
Incidence of BPD
Time frame: 36 weeks PMA
Mortality rate
Time frame: 36 weeks PMA
Incidence of severe intraventricular hemorrhage
Time frame: 28-days since birth
Incidence of necrotizing enterocolitis (Bell stage ≥ IIa)
Time frame: 36 weeks PMA
Incidence of periventricular leukomalacia
Time frame: 36 weeks PMA
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.